- Home
- MHH vs IMUX Comparison
MHH vs IMUX Comparison
Compare MHH & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHH | IMUX |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 85.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MHH | IMUX |
|---|---|---|
| Price | $6.87 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 20.0K | ★ 1.6M |
| Earning Date | 02-18-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,657,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $6.20 | $0.51 |
| 52 Week High | $14.75 | $1.39 |
Technical Indicators
Market Signals| Indicator | MHH | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 44.80 | 43.59 |
| Support Level | $6.80 | $0.59 |
| Resistance Level | $7.34 | $0.72 |
| Average True Range (ATR) | 0.34 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 2.74 | 13.55 |
Price Performance
Historical ComparisonAbout MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.